



Dedicated To Life

August 11, 2022

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East)
Mumbai-400051

Code: Zyduslife

Re.: **Newspaper publication**

Dear Sir / Madam,

Please find attached the newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter ended on June 30, 2022 in Financial Express on August 11, 2022.

Please find the same in order.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above



**Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]**

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0100 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter Ended 30/06/2022

Sr. No.	Particulars	Rupees in Million			
		3 Months ended 30/06/2022 (Unaudited)	Preceding 3 Months ended 31/03/2022 (Unaudited)	Corresponding 3 months ended 30/06/2021 in the previous year (Unaudited)	Previous year ended 31/03/2022 (Audited)
1	Total income from operations	40,727	38,638	40,018	1,52,652
2	Net Profit for the period before exceptional items and tax	6,839	5,729	8,029	27,254
3	Net Profit for the period after exceptional items but before tax	6,810	5,729	8,029	28,381
4	Net Profit for the period from continuing operations	5,266	4,124	5,972	22,416
5	Profit after tax from discontinued operations	(83)	(150)	(100)	22,457
6	Net Profit for the period after tax and Non-Controlling Interest	5,183	3,974	5,872	44,873
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	3,608	3,319	5,468	43,832
8	Paid-up equity share capital (Face value Re. 1/-)	1,024	1,024	1,024	1,024
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)				1,68,972
10	Earnings per share for continuing operations (not annualised for the quarter)				
a	Basic (Rs.)	5.14	4.03	5.83	21.90
b	Diluted (Rs.)	5.14	4.03	5.83	21.90
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter)				
a	Basic (Rs.)	5.06	3.88	5.74	43.83
b	Diluted (Rs.)	5.06	3.88	5.74	43.83

Note:

[1] The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel
Managing Director

Ahmedabad, August 10, 2022


Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Valshnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0100 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter Ended 30/06/2022

Sr. No.	Particulars	Rupees in Million			
		3 Months ended	Preceding 3	Corresponding	Previous year ended
		30/06/2022	Months ended	30/06/2021 in	
(Unaudited)	31/03/2022	the previous year	31/03/2022		
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	40,727	38,638	40,018	1,52,652
2	Net Profit for the period before exceptional items and tax	6,839	5,729	8,029	27,254
3	Net Profit for the period after exceptional items but before tax	6,810	5,729	8,029	28,381
4	Net Profit for the period from continuing operations	5,266	4,124	5,972	22,416
5	Profit after tax from discontinued operations	(83)	(150)	(100)	22,457
6	Net Profit for the period after tax and Non-Controlling Interest	5,183	3,974	5,872	44,873
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	3,608	3,319	5,468	43,832
8	Paid-up equity share capital (Face value Re. 1/-)	1,024	1,024	1,024	1,024
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)				1,68,972
10	Earnings per share for continuing operations (not annualised for the quarter)				
a	Basic (Rs.)	5.14	4.03	5.83	21.90
b	Diluted (Rs.)	5.14	4.03	5.83	21.90
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter)				
a	Basic (Rs.)	5.06	3.88	5.74	43.83
b	Diluted (Rs.)	5.06	3.88	5.74	43.83

Note:

[1] The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website: www.zyduslife.com or the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Shvil P. Patel
Managing Director

Ahmedabad, August 10, 2022